Bladder cancer specialist UroGen Pharma (Nasdaq: URGN) has appointed David Lin as chief commercial officer.
The New Jersey, USA-based firm has made the appointment in the run-up to a potential launch for lead candidate UGN-102 (mitomycin).
Mr Lin joins UroGen with experience from his tenure at Bristol Myers Squibb (NYSE: BMY), where he successfully launched two CAR T therapies as head of US cell therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze